Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-03

Study Completion Date

2026-01-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treatment and continue with active surveillance instead while keeping their MRD-negative remission status for at least 1 year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Discontinuation Study

NCT05866757

Multiple Myeloma Cancer Hematologic Cancer

RECRUITING NA

Multiple Myeloma Patient Registry

NCT03180853

Multiple Myeloma

TERMINATED

Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

NCT01617213

Multiple Myeloma

TERMINATED PHASE2

Lenalidomide Maintenance in Plasma Cell Myeloma

NCT02538198

Plasma Cell Myeloma

ACTIVE_NOT_RECRUITING PHASE2

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

NCT06182774

Multiple Myeloma

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasma Cell Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MRD-Negative Participants

Cessation of continuous matinenace therapy

Intervention Type OTHER

Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cessation of continuous matinenace therapy

Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with plasma cell myeloma treated with any number of prior lines of therapy, who at the time of study enrollment have had sustained MRD-negativity at a given timepoint and a subsequent time point with an interval of 3 or more years while on continuous maintenance therapy. MRD-negativity is defined per the International Myeloma Working Group Consensus Panel.
* MRD positivity will be defined by detection of 1 or more neoplastic plasma cells in 10\^5 nucleated cells by flow cytometry as per IMWG criteria (i.e., sensitivity of 10-5)
* Age \>/= 18 years with ECOG performance status \</= 2
* Patients must be able to understand and be willing to sign a voluntary informed consent form and agree to compliance with the protocol schedule; with the knowledge that they may withdraw consent at any time without impact on future medical care

Exclusion Criteria

* Patients found to be MRD-positive at time of screening
* Patients with plasma cell leukemia or other disorder of plasma cell neoplasm
* Patient who are receiving other therapy with the intent of treating myeloma with the exception of bisphosphonates
* Patients being treated for another, potentially life-limiting malignancy with 3-year lead-in to study enrollment, with the exception of non-melanoma skin cancer or in situ malignancy or malignancies that have received definitive curative therapy
* Prior organ transplant or condition requiring immunosuppressive therapy
* Prior allogeneic hematopoietic cell transplant
* Patients with any other ongoing, concomitant, comorbid illness including but not limited to uncontrolled diabetes, NYHA class III or IV heart failure, uncontrolled coronary artery disease/arrhythmia, psychiatric or social disorder that would compromise compliance with the study schema

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No